 |
Alpha1-proteinase inhibitor (human) |
|---|---|
| Trade Name | Prolastin |
| Orphan Indication | For replacement therapy in the alpha-1-proteinase inhibitor congenital deficiency state |
| USA Market Approval | USA |
| USA Designation Date | 1984-12-07 00:00:00 |
| Sponsor | Bayer Corporation;Pharmaceutical Division, Biological Products, 400 Morgan Lane;New Haven, Connecticut, 06516 |
